{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:06:49Z","timestamp":1793639209669,"version":"4.5.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.metabol.2017.10.007","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T01:48:13Z","timestamp":1511401693000},"page":"15-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Juvenile Paget disease"],"prefix":"10.1016","volume":"80","author":[{"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Cundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2017.10.007_bb0005","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0022-3476(56)80143-1","article-title":"Fragile bones and macrocranium","volume":"49","author":"Bakwin","year":"1956","journal-title":"J Pediatr"},{"key":"10.1016\/j.metabol.2017.10.007_bb0010","first-page":"292","article-title":"Hyperostosis corticalis deformans juvenilis: unfamiliar generalized osteopathy in 2 siblings","volume":"13","author":"Swoboda","year":"1958","journal-title":"Helv Paediatr Acta"},{"key":"10.1016\/j.metabol.2017.10.007_bb0015","first-page":"185","article-title":"Osteitis deformans (Paget's disease) in an 11year old boy","volume":"13","author":"Choremis","year":"1958","journal-title":"Helv Paediatr Acta"},{"key":"10.1016\/j.metabol.2017.10.007_bb0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMoa013096","article-title":"Osteoprotegerin deficiency and juvenile Paget's disease","volume":"347","author":"Whyte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.10.007_bb0025","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/hmg\/11.18.2119","article-title":"A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype","volume":"11","author":"Cundy","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.metabol.2017.10.007_bb0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1196\/annals.1346.016","article-title":"Paget's disease of bone and genetic disorders of RANKL\/OPG\/RANK\/NF-kappaB signaling","volume":"1068","author":"Whyte","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.metabol.2017.10.007_bb0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1210\/jc.2016-2905","article-title":"Loss of functional osteoprotegerin: more than a skeletal problem","volume":"102","author":"Grasemann","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0040","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJMoa013096","article-title":"Osteoprotegerin deficiency and juvenile Paget's disease (author's reply)","volume":"347","author":"Whyte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.10.007_bb0045","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1359\/jbmr.2003.18.12.2095","article-title":"Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype","volume":"18","author":"Chong","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2017.10.007_bb0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2017.10.007_bb0060","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12020-012-9705-0","article-title":"Genotype-phenotype correlation in juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene","volume":"42","author":"Brunetti","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.metabol.2017.10.007_bb0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bone.2014.07.034","article-title":"Novel homozygous mutations in the osteoprotegerin gene TNFRSF11B in two unrelated patients with juvenile Paget's disease","volume":"68","author":"Naot","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.10.007_bb0070","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1074\/jbc.273.9.5117","article-title":"Characterization of structural domains of human osteoclastogenesis inhibitory factor","volume":"273","author":"Yamaguchi","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2017.10.007_bb0075","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.metabol.2017.10.007_bb0080","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2017.10.007_bb0085","series-title":"ASBMR 2003 annual meeting","first-page":"S373","article-title":"Juvenile Paget's disease: molecular analysis of TNFRSF11B encoding osteoprotegerin indicates homozygous deactivating mutations from consanguinity as the predominant etiology","volume":"18","author":"Mumm","year":"2003"},{"key":"10.1016\/j.metabol.2017.10.007_bb0090","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.biocel.2006.11.008","article-title":"RANK ligand","volume":"39","author":"Blair","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0095","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2013-1143","article-title":"Effects of RANK-ligand antibody (Denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease","volume":"98","author":"Grasemann","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0100","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bone.2004.12.004","article-title":"An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation","volume":"36","author":"Janssens","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.10.007_bb0105","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1359\/jbmr.070307","article-title":"Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B \u201cBalkan\u201d mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels","volume":"22","author":"Whyte","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0110","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00774-010-0198-8","article-title":"Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease","volume":"28","author":"Polyzos","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0115","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ajmg.a.37536","article-title":"Auricular ossification: a newly recognized feature of osteoprotegerin-deficiency juvenile Paget disease","volume":"170a","author":"Gottesman","year":"2016","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.metabol.2017.10.007_bb0120","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2006-0479","article-title":"Sporadic hyperphosphatasia syndrome featuring periostitis and accelerated skeletal turnover without receptor activator of nuclear factor-kappaB, osteoprotegerin, or sequestosome-1 gene defects","volume":"92","author":"Simsek","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3325\/cmj.2015.56.145","article-title":"Polymorphisms of CSF1 and TM7SF4 genes in a case of mild juvenile Paget's disease found using next-generation sequencing","volume":"56","author":"Donath","year":"2015","journal-title":"Croat Med J"},{"key":"10.1016\/j.metabol.2017.10.007_bb0130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bone.2014.07.019","article-title":"Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK","volume":"68","author":"Whyte","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.10.007_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.berh.2007.11.005","article-title":"Juvenile Paget's disease, familial expansile osteolysis and other genetic osteolytic disorders","volume":"22","author":"Ralston","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0140","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s002470050525","article-title":"Involvement of the skull base and vault in chronic idiopathic hyperphosphatasia","volume":"29","author":"Mazzanti","year":"1999","journal-title":"Pediatr Radiol"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2017.10.007_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00256-006-0176-3","article-title":"Hyperphosphatasia with massive osteoectasia: a 45-year follow-up","volume":"36","author":"McCarthy","year":"2007","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0150","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s002470050708","article-title":"Calcitonin treatment in osteoectasia with hyperphosphatasia (juvenile Paget's disease): radiographic changes after treatment","volume":"29","author":"Tuysuz","year":"1999","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2265.1976.tb03843.x","article-title":"Hereditary bone dysplasia with hyperphosphatasaemia: response to synthetic human calcitonin","volume":"5","author":"Horwith","year":"1976","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2017.10.007_bb0160","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2106\/00004623-197153020-00010","article-title":"Chronic idiopathic hyperphosphatasia associated with pseudoxanthoma elasticum","volume":"53","author":"Mitsudo","year":"1971","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.metabol.2017.10.007_bb0165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.nbd.2013.04.008","article-title":"Loss of osteoprotegerin expression in the inner ear causes degeneration of the cochlear nerve and sensorineural hearing loss","volume":"56","author":"Kao","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.metabol.2017.10.007_bb0170","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/archophthalmol.2010.76","article-title":"Ocular manifestations of juvenile Paget disease","volume":"128","author":"Kerr","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0175","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3928\/0191-3913-19891101-13","article-title":"Visual impairment in a case of juvenile Paget's disease with pseudoxanthoma elasticum: an eleven year follow up","volume":"26","author":"Sharif","year":"1989","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.metabol.2017.10.007_bb0180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/archderm.1975.01630140129023","article-title":"Pseudoxanthoma elasticum in hyperphosphatasia","volume":"111","author":"Fretzin","year":"1975","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0185","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1210\/jcem-62-3-583","article-title":"Response to parathyroid hormone and 1,25-dihydroxyvitamin D3 of bone-derived cells isolated from normal children and children with abnormalities in skeletal development","volume":"62","author":"Silve","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0190","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fgene.2013.00022","article-title":"Fibroblast involvement in soft connective tissue calcification","volume":"4","author":"Ronchetti","year":"2013","journal-title":"Front Genet"},{"key":"10.1016\/j.metabol.2017.10.007_bb0195","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3174\/ajnr.A0755","article-title":"Bilateral cavernous internal carotid aneurysms in a child with juvenile paget disease and osteoprotegerin deficiency","volume":"29","author":"Allen","year":"2008","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0200","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jclinane.2015.03.041","article-title":"Unanticipated difficult intubation in a patient with juvenile Paget disease","volume":"27","author":"Patnaik","year":"2015","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.metabol.2017.10.007_bb0205","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3342\/ceo.2008.1.4.224","article-title":"Juvenile Paget's disease with paranasal sinus aplasia","volume":"1","author":"Bae","year":"2008","journal-title":"Clin Exp Otorhinolaryngol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bone.2004.03.013","article-title":"Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy","volume":"35","author":"Tau","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.10.007_bb0215","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jbmr.5650110118","article-title":"Juvenile Paget disease: life-long features of a mildly affected young woman","volume":"11","author":"Golob","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0220","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/jbmr.5650090519","article-title":"Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate","volume":"9","author":"Singer","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0225","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM200211143472015","article-title":"Osteoprotegerin deficiency and juvenile Paget's disease","volume":"347","author":"Hofbauer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.10.007_bb0230","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1210\/jc.2013-3762","article-title":"Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency (\u201cBalkan\u201d mutation in the TNFRSF11B gene)","volume":"99","author":"Polyzos","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0235","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/jbmr.1868","article-title":"Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation","volume":"28","author":"Saki","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0240","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2008-1046787","article-title":"Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial","volume":"40","author":"Anastasilakis","year":"2008","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0245","first-page":"271","article-title":"Periostin and sclerostin levels in juvenile Paget's disease","volume":"14","author":"Polyzos","year":"2017","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0250","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-0031-1284365","article-title":"Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment","volume":"119","author":"Polyzos","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.metabol.2017.10.007_bb0255","series-title":"Genetics of bone biology and skeletal disease","first-page":"309","article-title":"Mendelian disorders of RANKL\/OPG\/RANK","author":"Whyte","year":"2013"},{"key":"10.1016\/j.metabol.2017.10.007_bb0260","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1002\/ajmg.a.31373","article-title":"A newly recognized polyosteolysis\/hyperostosis syndrome","volume":"140","author":"Kantaputra","year":"2006","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.metabol.2017.10.007_bb0265","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1359\/jbmr.040210","article-title":"Loss of chaotic trabecular structure in OPG-deficient juvenile Paget's disease patients indicates a chaogenic role for OPG in nonlinear pattern formation of trabecular bone","volume":"19","author":"Salmon","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0270","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00774-008-0852-6","article-title":"Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone","volume":"26","author":"Avramidis","year":"2008","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0275","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1055\/s-0029-1233491","article-title":"The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget's disease of bone","volume":"41","author":"Polyzos","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0280","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1016\/j.metabol.2017.06.003","article-title":"Lipodystrophy: time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications","volume":"72","author":"Polyzos","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.10.007_bb0285","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/jbmr.3156","article-title":"Treating Paget's disease-why and how much?","volume":"32","author":"Cundy","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0290","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1302\/0301-620X.59B4.562883","article-title":"Familial idiopathic hyperphosphatasia: a study of two young siblings treated with porcine calcitonin","volume":"59-b","author":"Blanco","year":"1977","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.metabol.2017.10.007_bb0295","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/bmj.4.5835.267","article-title":"Paget's disease in a 5-year-old: acute response to human calcitonin","volume":"4","author":"Woodhouse","year":"1972","journal-title":"Br Med J"},{"key":"10.1016\/j.metabol.2017.10.007_bb0300","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1259\/0007-1285-47-553-9","article-title":"Healing of the bones in juvenile Paget's disease treated by human calcitonin","volume":"47","author":"Doyle","year":"1974","journal-title":"Br J Radiol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2214\/ajr.129.1.29","article-title":"Calcitonin treatment in hereditary bone dysplasia with hyperphosphatasemia: a radiographic and histologic study of bone","volume":"129","author":"Whalen","year":"1977","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0310","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2214\/ajr.132.4.541","article-title":"Familial hyperphosphatasemia: diagnosis in early infancy and response to human thyrocalcitonin therapy","volume":"132","author":"Dunn","year":"1979","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0315","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s002640050029","article-title":"Management of primary idiopathic hyperphosphatasemia with calcitonin: a case report","volume":"20","author":"Roth","year":"1996","journal-title":"Int Orthop"},{"key":"10.1016\/j.metabol.2017.10.007_bb0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0221-8747(81)80017-3","article-title":"Three adult cases resembling hereditary bone dysplasia","volume":"3","author":"Kraszeski","year":"1981","journal-title":"Metab Bone Dis Relat Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0325","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1586\/eem.09.35","article-title":"Paget's disease of bone: emphasis on treatment with zoledronic acid","volume":"4","author":"Polyzos","year":"2009","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0330","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.10.007_bb0335","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa050893","article-title":"Recombinant osteoprotegerin for juvenile Paget's disease","volume":"353","author":"Cundy","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.10.007_bb0340","first-page":"642","article-title":"Chronic idiopathic hyperphosphatasia. Report of a case treated with pamidronate and a review of the literature","volume":"19","author":"Spindler","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.metabol.2017.10.007_bb0345","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0169-6009(92)90924-3","article-title":"Familial idiopathic hyperphosphatasia (FIH): response to long-term treatment with pamidronate (APD)","volume":"19","author":"Cassinelli","year":"1992","journal-title":"Bone Miner"},{"key":"10.1016\/j.metabol.2017.10.007_bb0350","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1515\/JPEM.2000.13.2.217","article-title":"Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia","volume":"13","author":"Demir","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0355","first-page":"354","article-title":"Juvenile Paget's disease","volume":"46","author":"Indumathi","year":"2009","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.metabol.2017.10.007_bb0360","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1359\/jbmr.040127","article-title":"Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy","volume":"19","author":"Cundy","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0365","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1359\/jbmr.080812","article-title":"Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin","volume":"24","author":"Kanzaki","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0370","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women","volume":"16","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.10.007_bb0375","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.metabol.2017.10.007_bb0380","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd3930","article-title":"Clinical targeting of the TNF and TNFR superfamilies","volume":"12","author":"Croft","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.metabol.2017.10.007_bb0385","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with Denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0390","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.10.007_bb0395","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517302810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517302810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:16:12Z","timestamp":1758428172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049517302810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":79,"alternative-id":["S0026049517302810"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2017.10.007","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Juvenile Paget disease","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2017.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}